Table 5 Diagnostic performance of the combination of NDKA and FIT for the detection of advanced neoplasia and advanced adenomas based on the screening cohort.
From: Evaluation of serum nucleoside diphosphate kinase A for the detection of colorectal cancer
Cut-off | Specificity % (95% CI) | Advanced neoplasia (n = 57) | Advanced adenomas (n = 53) | ||||||
|---|---|---|---|---|---|---|---|---|---|
Sensitivity % (95% CI) | PPV % (95% CI) | NPV % (95% CI) | Sensitivity % (95% CI) | PPV % (95% CI) | NPV % (95% CI) | Proximal n = 14 (% detection) | Distal n = 39 (% detection) | ||
FIT ≥100 ng/mL | 98.24 (96.6–99.2) | 36.84 (24.4–50.7) | 72.44 (44.1–86.0) | 92.53 (91.3–94.3) | 32.08 (19.9–46.3) | 68.02 (46.5–85.1) | 92.53 (89.9–94.8) | 7.14 | 41.03 |
NDKA ≥82.21 pg/mL and/or FIT ≥100 ng/mL | 88.32 (84.9–91.1) | 49.12 (35.8–62.6) | 34.57 (24.6–46.0) | 93.26 (90.3–95.4) | 45.28 (31.8–59.4) | 31.12 (21.4–42.9) | 93.26 (90.3–95.4) | 28.57 | 51.28 |
NDKA ≥94.79 pg/mL and/or FIT ≥100 ng/mL | 93.17 (90.3–95.2) | 45.61 (32.6–59.2) | 45.61 (32.6–59.2) | 93.17 (90.3–95.2) | 41.51 (28.4–55.8) | 41.49 (28.4–55.8) | 93.17 (90.3–95.2) | 28.57 | 46.15 |
